UCB SA (UCB.BR)

EUR 146.5

(-0.58%)

EBITDA Summary of UCB SA

  • UCB SA's latest annual EBITDA in 2023 was 1.26 Billion EUR , down -1.52% from previous year.
  • UCB SA's latest quarterly EBITDA in 2024 Q2 was 644 Million EUR , down 0.0% from previous quarter.
  • UCB SA reported an annual EBITDA of 1.16 Billion EUR in 2022, down -32.99% from previous year.
  • UCB SA reported an annual EBITDA of 1.59 Billion EUR in 2021, up 10.44% from previous year.
  • UCB SA reported a quarterly EBITDA of 794 Million EUR for 2023 Q2, down 0.0% from previous quarter.
  • UCB SA reported a quarterly EBITDA of N/A for 2023 FY, down -1.52% from previous quarter.

Annual EBITDA Chart of UCB SA (2023 - 2002)

Historical Annual EBITDA of UCB SA (2023 - 2002)

Year EBITDA EBITDA Growth
2023 1.26 Billion EUR -1.52%
2022 1.16 Billion EUR -32.99%
2021 1.59 Billion EUR 10.44%
2020 1.3 Billion EUR -4.72%
2019 1.33 Billion EUR -0.21%
2018 1.4 Billion EUR 10.15%
2017 1.27 Billion EUR 23.64%
2016 1.08 Billion EUR 24.0%
2015 829 Million EUR 38.17%
2014 600 Million EUR 10.29%
2013 544 Million EUR -12.54%
2012 637 Million EUR -16.62%
2011 610 Million EUR 2.05%
2010 430 Million EUR -44.41%
2009 1 Billion EUR 74.63%
2008 270 Million EUR 6.96%
2007 545 Million EUR 0.28%
2006 678 Million EUR 18.98%
2005 503 Million EUR -28.88%
2004 355 Million EUR 4.01%
2003 797.61 Million EUR -15.45%
2002 829.74 Million EUR 0.0%

Peer EBITDA Comparison of UCB SA

Name EBITDA EBITDA Difference
Nicox S.A. -16.23 Million EUR 7915.002%
European Medical Solutions 59 Thousand EUR -2150747.458%
FERMENTALG -10.51 Million EUR 12174.215%
argenx SE -199.5 Million EUR 736.071%
BioSenic S.A. -6.79 Million EUR 18772.749%
Celyad Oncology SA -7.76 Million EUR 16446.773%
Hyloris Pharmaceuticals SA -14.98 Million EUR 8571.295%
Onward Medical N.V. -35.23 Million EUR 3701.635%
Oxurion NV -16.72 Million EUR 7685.63%
PHAXIAM Therapeutics S.A. -22.93 Million EUR 5634.235%
Financière de Tubize SA 184.57 Thousand EUR -687440.296%